Dateline Drops 8% Despite Strong Colosseum Gold Assays as Small Caps Face Market Rotation
Dateline Shares Slip on Sentiment as New Colosseum Drill Results Strengthen Feasibility Pathway Dateline Resources (ASX: DTR) saw an interesting…
TMK Energy Rockets 30 Percent as Gurvantes Gas Output Hits Record Levels
TMK Energy Jumps on Market as Gurvantes Production Beats 2025 Targets with Record Flows TMK Energy (ASX: TMK) surged 30%…
AML3D Surges After Landing 9th US Order with A$1.7m ARCEMY X Deal
AML3D Extends US Momentum, Stock Rises on Major A$1.69m ARCEMY X Sale to FasTech AML3D (ASX: AL3) continues to build…
Metallium Signs Binding 10 Year Deal with New Frontier Minerals After Record Processing Results
Record FJH Results Drive Metallium’s Binding Ten-Year Deal with New Frontier Minerals Metallium (ASX: MTM) delivered a major step forward…
Prescient Therapeutics (ASX:PTX): It has taken the plunge into a Phase 2 trial against T-Cell Lymphoma
There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…
Here Are 5 Times Activist Short Sellers Brought Down a Company; And 5 Times They Failed
Last week’s attack on IperionX (ASX:IPX) by Activist Short Sellers was not the first time this has happened, but we…
IBM (NYSE:IBM) may no longer be a monopolist, but it is an emerging player in the lucrative AI, Cloud and Quantum spaces
‘No one got fired for buying an IBM‘. Yes, that was an actual saying, sometimes in those exact words, otherwise…
BHP (ASX: BHP) Falls 1% After $2.2bn Court Ruling: Buy, Hold, or Avoid?
BHP Group (ASX: BHP) fell around 1% on Friday after a UK High Court ruled the mining giant is liable…
Race Oncology (ASX: RAC) Launches Lung Cancer Program: Buy the Breakout or Wait for a Pullback?
Race Oncology (ASX: RAC) unveiled two new clinical programs, expanding its lead drug RC220 into acute myeloid leukaemia and EGFR-mutated…
Is Pro Medicus Still a Buy at 150x Earnings? What the Valuation Means for Investors
Pro Medicus (ASX: PME) trades at a valuation that defies conventional wisdom. Despite a 25% pullback from July’s $336 peak…
TPG Plunges 32% After Ex-Dividend: Is This a Buying Opportunity?
TPG Telecom (ASX: TPG) plunged 32% this week to $3.80, triggering panic among investors unfamiliar with ex-dividend mechanics. But here’s what…
How Mobile Payments Are Redefining Digital Trust in Australia
Mobile payments have become ubiquitous, not just for Aussies, but on a global scale. Google Wallet, Apple Pay, Samsung Pay,…
Calix (ASX: CXL) Jumps 32% as Landmark Rio Tinto Deal
Calix Shares Surge 32% After Signing Transformational Green-Steel Deal With Rio Tinto Calix (ASX: CXL) surged 32% today and, in…
3D Energi Soars 43% After Confirming Two Gas Bearing Reservoirs
3D Energi Leaps 43% on Gas Intersection Update, Encouraging but Not Yet a Commercial Discovery 3D Energi (ASX: TDO) delivered…
Island Pharmaceuticals Soars 32% After FDA Clears Galidesivir for Animal Rule Pathway
Island Pharmaceuticals Surges 32 Percent on Transformational FDA Decision for Galidesivir Island Pharmaceuticals (ASX: ILA) jumped 32% this morning after…